Bristol Myers Squibb reported total revenues of $11.5 billion for the quarter, representing a 3% increase year-over-year, or 1% growth when excluding foreign exchange effects. Non-GAAP diluted EPS decreased by 12% to $1.58, while GAAP diluted EPS grew 9% to $1.31. Financial performance was primarily driven by a 12% revenue jump in the company's Growth Portfolio to $6.2 billion, led by strong uptake for Camzyos, Breyanzi, and Reblozyl, which helped mitigate a 6% contraction in the Legacy Portfolio due to generic competition.
Note: Bristol Myers Squibb's FY'25 ended on December 31, 2025. Q1 FY'26 ended on March 31, 2026.
Bristol Myers Squibb is advancing the commercial rollout of Cobenfy, a first-in-class oral medication for schizophrenia that marks the first new pharmacological approach for the condition in over thirty years. The company is actively executing clinical trials to expand Cobenfy's indications into other high-need areas, including Alzheimer's disease psychosis and agitation. This strategic expansion into neuropsychiatry represents a multi-billion dollar long-term growth catalyst designed to diversify the company's revenue streams as legacy assets face patent expiries.
Below are key drivers of Bristol Myers Squibb's value that present opportunities for upside or downside to the current Trefis price estimate:
For additional details, select a division from the interactive Trefis split for Bristol Myers Squibb at the top of the page.
Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases across oncology, hematology, immunology, cardiovascular, and neuroscience sectors.
The oncology and legacy cardiovascular drug segments remain the primary contributors to the company's overall valuation due to established volume baselines.
Eliquis remains a leading oral anticoagulant globally, generating multi-billion dollar annual sales and maintaining an exceptional competitive moat within thrombotic disease management despite ongoing pricing reviews.
Opdivo continues to anchor the company's oncology segment, leveraging a deep clinical track record across multiple tumor indications to sustain strong underlying physician preference and robust global hospital channel volume.
The biopharmaceutical industry is rapidly adopting machine learning models to optimize drug design and target selection. Bristol Myers Squibb is utilizing artificial intelligence to streamline late-stage development and clinical operations, aiming to achieve a 30% reduction in cycle times compared to historical drug development timelines.
Management is executing a strategic transition by actively shifting resources away from the shrinking legacy portfolio and focusing capital on the higher-margin growth portfolio. This pivot relies on ramping up newer treatments to systematically replace revenues lost to generic competition.
